Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Gilbert

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
JAMA|February 15, 2001
Virologic and regimen termination surrogate end points in AIDS clinical trialsP B Gilbert, V DeGruttola, S M Hammer, et al.
Biometrika|January 19, 2021
General regression model for the subdistribution of a competing risk under left-truncation and right-censoringA Bellach, M R Kosorok, P B Gilbert, et al.
Biometrika|February 13, 2018
Doubly robust nonparametric inference on the average treatment effectD Benkeser, M Carone, M J Van Der Laan, et al.
AIDS (London, England)|September 21, 2000
Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trialP B Gilbert, H J Ribaudo, L Greenberg, et al.
AIDS Research and Human Retroviruses|October 6, 2000
Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimensP B Gilbert, G J Hanna, V De Gruttola, et al.
Vaccine|June 12, 2003
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsP B Gilbert, Y-L Chiu, M Allen, et al.
AIDS (London, England)|August 16, 2001
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppressionD V Havlir, P B Gilbert, K Bennett, et al.
Pediatric Transplantation|November 30, 2011
Allospecific CD154 + T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantationRakesh Sindhi, Chethan Ashokkumar, Brandon W Higgs, et al.
Vaccine|October 27, 2016
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trialT Hertz, M G Logan, M Rolland, et al.
The New England Journal of Medicine|October 22, 2015
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineD E Neafsey, M Juraska, T Bedford, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
JAMA|February 15, 2001
Virologic and regimen termination surrogate end points in AIDS clinical trialsP B Gilbert, V DeGruttola, S M Hammer, et al.
Biometrika|January 19, 2021
General regression model for the subdistribution of a competing risk under left-truncation and right-censoringA Bellach, M R Kosorok, P B Gilbert, et al.
Biometrika|February 13, 2018
Doubly robust nonparametric inference on the average treatment effectD Benkeser, M Carone, M J Van Der Laan, et al.
AIDS (London, England)|September 21, 2000
Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trialP B Gilbert, H J Ribaudo, L Greenberg, et al.
AIDS Research and Human Retroviruses|October 6, 2000
Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimensP B Gilbert, G J Hanna, V De Gruttola, et al.
Vaccine|June 12, 2003
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsP B Gilbert, Y-L Chiu, M Allen, et al.
AIDS (London, England)|August 16, 2001
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppressionD V Havlir, P B Gilbert, K Bennett, et al.
Pediatric Transplantation|November 30, 2011
Allospecific CD154 + T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantationRakesh Sindhi, Chethan Ashokkumar, Brandon W Higgs, et al.
Vaccine|October 27, 2016
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trialT Hertz, M G Logan, M Rolland, et al.
The New England Journal of Medicine|October 22, 2015
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineD E Neafsey, M Juraska, T Bedford, et al.
Pageof 2